Abeona Therapeutics Incの推定成長EPS Q/Q
Abeona Therapeutics Incの推定成長EPS Q/Qは何ですか。
Abeona Therapeutics Incの推定成長EPS Q/Qは-82.86%です。
推定成長EPS Q/Qの定義は何ですか。
期待される四半期ごとのEPS成長率は、過去四半期の業績と比較して、次の四半期の企業EPSの推定増加です。
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
NASDAQのセクタHealth Careにおける推定成長EPS Q/Qの企業と比べるAbeona Therapeutics Inc
Abeona Therapeutics Incは何をしますか。
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Abeona Therapeutics Incと類似の推定成長eps q/q
- Trecora Resourcesの推定成長EPS Q/Qは-83.33%です。
- Apollo Medical Incの推定成長EPS Q/Qは-83.33%です。
- Ultrapar Participacoes S.Aの推定成長EPS Q/Qは-83.33%です。
- Brooks Automationの推定成長EPS Q/Qは-82.98%です。
- Medical Facilitiesの推定成長EPS Q/Qは-82.93%です。
- Morphosys AGの推定成長EPS Q/Qは-82.91%です。
- Abeona Therapeutics Incの推定成長EPS Q/Qは-82.86%です。
- Uber Technologies Incの推定成長EPS Q/Qは-82.81%です。
- Spirit Airlinesの推定成長EPS Q/Qは-82.81%です。
- Spirit Airlines Incの推定成長EPS Q/Qは-82.81%です。
- Nebius N.Vの推定成長EPS Q/Qは-82.76%です。
- Kirkland`s Incの推定成長EPS Q/Qは-82.61%です。
- Alkermes plcの推定成長EPS Q/Qは-82.61%です。